Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
RS Research logo — Clinically-validated biotech company for targeted therapies,...

RS Research

Clinically-validated biotech company for targeted therapies, disrupting the efficacy-toxicity trade-off.

Founded 2015 Turkey Turkey 30 employees Series A Total: $14.00M Biotechnology, Pharmaceutical

General Information

Company Name RS Research
Founded Year 2015
Location Turkey Turkey
Founders / Decision Makers
Team member
Employees 30
Industries Biotechnology, Pharmaceutical
Funding Stage Series A
Business Model B2B, B2D
Revenue Model Licensing, Product Sales, Performance Based
Offices as of Aug 2026
Istanbul, Turkey Epalinges, Switzerland
Social

BounceWatch is an independent company data service, not affiliated with RS Research. To contact RS Research, visit rsresearch.net.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does RS Research compare?

A PDF of RS Research and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting RS Research soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Program Acceptance Oct 13, 2026

RS Research has been selected to join the inaugural CapitalXchange Startup Cohort, organized by Global Health Exhibition.

Get alerts when RS Research shows new signals

About RS Research

RS Research is a clinical-stage biotechnology start-up headquartered in Turkey that is at the forefront of developing smart nanomedicines for targeted chemotherapy. Established in 2015, the company leverages its innovative drug delivery platform, Sagitta®, aiming to provide a “Cure With a Smile” through an enhanced therapeutic index for patients battling cancer.

Focusing within the Biotechnology and Pharmaceutical industries, RS Research has demonstrated a strong pipeline by strategically intertwining scientific discovery with practical industry applications. The company’s last funding round was a $12.00M Series A investment in December 2021, backed by reputable investors including Gen Ilac, OneLife Ventures, Eczacıbasi Momentum, and Gen Pharmaceuticals. This investment underscores confidence in RS Research’s potential to revolutionize cancer treatment, positioning them as a promising venture for forward-thinking investors.

Business keywords: clinical-stage biotechnology, smart nanomedicines, targeted chemotherapy, drug delivery platform, Sagitta®, cancer therapy, therapeutic index improvement, nanocarrier platform, preclinical services, biosimilar characterization, in vivo experimentation, contract manufacturing organization, cytotoxic-capable production, GMP certified facility, oncology-focused innovation

Services & Products

Development of targeted oncology therapies
Sagitta® drug delivery platform
Clinical trials for cancer treatment

Target Customers

Oncologists Pharmaceutical companies Research institutions Healthcare providers

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $12.00M 4
Gen Ilac, OneLife Ventures +2
01 Dec 2021
Convertible Note €900.00K 1
ACT Venture Partners
ACT Venture Partners
01 Jan 2018
Early VC €1.10M 1
ACT Venture Partners
ACT Venture Partners
01 Apr 2017
Spinout Undisclosed 1
Boğaziçi University
01 Mar 2015

Latest News

View All
How research partnerships under the MSCA are driving innovation [Sponsored] — Tech
How research partnerships under the MSCA are driving innovation [Sponsored]
Tech Aug 12, 2026
Milyar dolarlık potansiyel — Bmag.com.tr
Milyar dolarlık potansiyel
Bmag.com.tr Oct 01, 2025
Prof. Dr. Rana Sanyal'a Avrupa Yenilik Konseyi'nden Ödül — Haberler.bogazici.edu.tr
Prof. Dr. Rana Sanyal'a Avrupa Yenilik Konseyi'nden Ödül
Haberler.bogazici.edu.tr May 17, 2025
Turcorn adayı firma sayısı 23 oldu! İşte Turcorn adayı firmalar! — Hwp.com.tr
Turcorn adayı firma sayısı 23 oldu! İşte Turcorn adayı firmalar!
Hwp.com.tr Mar 26, 2025
Prof. Dr. Rana Sanyal, Cartier Women's Initiative'de 2021 Bilim & Teknoloji Öncüsü kategorisine seçi... — Haberler.bogazici.edu.tr
Prof. Dr. Rana Sanyal, Cartier Women's Initiative'de 2021 Bilim & Teknoloji Öncüsü kategorisine seçildi
Haberler.bogazici.edu.tr Apr 27, 2021
Yerli biyoteknoloji girişimi RS Research, ACT Venture Partners’tan 900 bin Euro yatırım aldı — Egirisim.com
Yerli biyoteknoloji girişimi RS Research, ACT Venture Partners’tan 900 bin Euro yatırım aldı
Egirisim.com Jan 10, 2018

RS Research Alternatives & Competitors

View All Alternatives
RS Research vs
Cybrexa Therapeutics
Cybrexa Therapeutics United States

Changing the paradigm for cancer treatment through the development of antigen-independent peptide dr...

Series B
11 employees
Biotechnology, Health and Wellness
Compare RS Research vs Cybrexa Therapeutics
RS Research vs
Nanoligent
Nanoligent Spain

Our mision is to improve the life of patients by designing new drugs that selectively target affecte...

Seed
15 employees
Biotechnology, Pharmaceutical
Compare RS Research vs Nanoligent
RS Research vs
Shasqi
Shasqi United States

Targeting cancer with click chemistry

Series B
28 employees
Biotechnology, Health Care
View all alternatives

FAQ About RS Research

Clinically-validated biotech company for targeted therapies, disrupting the efficacy-toxicity trade-off.
RS Research was founded in 2015.
RS Research is headquartered in Turkey. As of Aug 2026, it also has offices in Istanbul, Turkey and Epalinges, Switzerland.
RS Research operates in Biotechnology and Pharmaceutical. Its work centres on clinical-stage biotechnology, smart nanomedicines, targeted chemotherapy and drug delivery platform. Its customers include Oncologists, Pharmaceutical companies and Research institutions.
RS Research has a B2B and B2D business model. Its revenue comes from Licensing, Product Sales and Performance Based.
RS Research has approximately 30 employees.
RS Research has completed 4 funding rounds, raising a total of $14.00M. The latest funding stage is Series A.
RS Research offers: Development of targeted oncology therapies, Sagitta® drug delivery platform, Clinical trials for cancer treatment.
Top alternatives and competitors to RS Research include Cybrexa Therapeutics, Nanoligent, Shasqi, Alterome Therapeutics, Inc, Pyxis Oncology. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
RS Research and Cybrexa Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for RS Research, https://bouncewatch.com/company/rs-research, updated 23 August 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes